Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
STX

Shield Therapeutics plc

STXLSEUnited KingdomHealthcareDrug Manufacturers - Specialty & GenericAIM

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the…more

P/B-4.41xROIC-231.0%
£49.86M
Market Cap
EV: £66.41M
MOM3
QUAL5
VAL—
RSK5
STX
£49.86M
Market Cap · EV £66.41M

Shield Therapeutics plc

MOM3
QUAL5
VAL—
RSK5

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the…more

Latest RNS from Shield Therapeutics plc

Analyst consensus: Buy

As of 21 Sept 2026, 3 analysts rate Shield Therapeutics plc a Buy, with 100% buy ratings and a mean price target of 17p (range 12p–23p), +247% vs the current price.

Strong buy: 0Buy: 3Hold: 0Sell: 0Strong sell: 0

Full analyst history →

More Healthcare companies